BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29155210)

  • 21. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The testosterone metabolite and neurosteroid 3alpha-androstanediol may mediate the effects of testosterone on conditioned place preference.
    Frye CA; Park D; Tanaka M; Rosellini R; Svare B
    Psychoneuroendocrinology; 2001 Oct; 26(7):731-50. PubMed ID: 11500254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor beta and the progression of prostate cancer: role of 5alpha-androstane-3beta,17beta-diol.
    Dondi D; Piccolella M; Biserni A; Della Torre S; Ramachandran B; Locatelli A; Rusmini P; Sau D; Caruso D; Maggi A; Ciana P; Poletti A
    Endocr Relat Cancer; 2010 Sep; 17(3):731-42. PubMed ID: 20562232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.
    Chen J; Yang Y; Xu D; Li J; Wu S; Jiang Y; Wang C; Yang Z; Zhao L
    Biochem Biophys Res Commun; 2021 Feb; 540():83-89. PubMed ID: 33450484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
    Penning TM; Burczynski ME; Jez JM; Hung CF; Lin HK; Ma H; Moore M; Palackal N; Ratnam K
    Biochem J; 2000 Oct; 351(Pt 1):67-77. PubMed ID: 10998348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3α-HSD type 2 (17β-HSD type 5), moderates the subjective effects of alcohol.
    Milivojevic V; Feinn R; Kranzler HR; Covault J
    Psychopharmacology (Berl); 2014 Sep; 231(17):3597-608. PubMed ID: 24838369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.
    Powell K; Semaan L; Conley-LaComb MK; Asangani I; Wu YM; Ginsburg KB; Williams J; Squire JA; Maddipati KR; Cher ML; Chinni SR
    Clin Cancer Res; 2015 Jun; 21(11):2569-79. PubMed ID: 25754347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.
    Zang T; Tamae D; Mesaros C; Wang Q; Huang M; Blair IA; Penning TM
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):342-355. PubMed ID: 27531846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype.
    Guerini V; Sau D; Scaccianoce E; Rusmini P; Ciana P; Maggi A; Martini PG; Katzenellenbogen BS; Martini L; Motta M; Poletti A
    Cancer Res; 2005 Jun; 65(12):5445-53. PubMed ID: 15958594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.
    Wang B; Wu S; Fang Y; Sun G; He D; Hsieh JT; Wang X; Zeng H; Wu K
    J Cell Mol Med; 2020 Oct; 24(20):12032-12043. PubMed ID: 32902124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurosteroid metabolites of testosterone and progesterone differentially inhibit ERK phosphorylation induced by amyloid β in SH-SY5Y cells and primary cortical neurons.
    Mendell AL; Chung BYT; Creighton CE; Kalisch BE; Bailey CDC; MacLusky NJ
    Brain Res; 2018 May; 1686():83-93. PubMed ID: 29477545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
    Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
    BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review.
    Karunasinghe N; Masters J; Flanagan JU; Ferguson LR
    Curr Cancer Drug Targets; 2017; 17(7):603-616. PubMed ID: 28359237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
    Hertzog JR; Zhang Z; Bignan G; Connolly PJ; Heindl JE; Janetopoulos CJ; Rupnow BA; McDevitt TM
    Prostate; 2020 Oct; 80(14):1223-1232. PubMed ID: 33258507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.
    Mohler JL; Titus MA; Bai S; Kennerley BJ; Lih FB; Tomer KB; Wilson EM
    Cancer Res; 2011 Feb; 71(4):1486-96. PubMed ID: 21303972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.
    Pérez-Palacios G; Santillán R; García-Becerra R; Borja-Cacho E; Larrea F; Damián-Matsumura P; González L; Lemus AE
    J Endocrinol; 2006 Sep; 190(3):805-18. PubMed ID: 17003281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
    Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
    Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.